Compare TUYA & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TUYA | QURE |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | China | Netherlands |
| Employees | N/A | 248 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2021 | 2013 |
| Metric | TUYA | QURE |
|---|---|---|
| Price | $2.31 | $17.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | $3.49 | ★ $44.92 |
| AVG Volume (30 Days) | 1.1M | ★ 1.7M |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $13.76 | $126.12 |
| Revenue Next Year | $11.90 | $200.43 |
| P/E Ratio | $27.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.87 | $8.19 |
| 52 Week High | $2.95 | $71.50 |
| Indicator | TUYA | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 46.28 | 51.01 |
| Support Level | $2.24 | $13.52 |
| Resistance Level | $2.46 | $18.37 |
| Average True Range (ATR) | 0.10 | 1.28 |
| MACD | -0.01 | 0.47 |
| Stochastic Oscillator | 33.33 | 83.12 |
Tuya Inc is an AI cloud platform service provider dedicated to bringing AI into everyday life. The group leverages its TuyaOpen open-source framework and universal AI Agent engines, including the AI Agent development platform, to integrate multimodal AI capabilities and reduce barriers to AI development. It drives the adoption of AI-powered lifestyles and speeds up the integration of AI with the physical world. It offers innovative physical AI solutions for smart devices, commercial use, and industry developers using cloud computing and spatial intelligence. It also provides a complete, open, and neutral global AIoT ecosystem. It builds a developer community that collaborates to create smart solutions grounded in sustainability, security, efficiency, agility, and openness.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.